Among these 9 potential targets, SOX2-clinically correlated with poor prognosis and aggressive BCa subtypes (Fig. 6C, D)-emerged as a key potential mediator of YTHDC2’s function in bladder cancer. Here, YTHDC2 is linked to urinary bladder cancer.